Nonadherence to protocol screenings in a screening trial for multiple cancers may be linked to higher overall mortality, excluding mortality due to cancers studied in the trial.
A lack of understanding of terminology, health care system distrust, and a lack of prostate cancer knowledge are among the barriers to genomic testing for prostate cancer and prostate cancer research participation among black men.
Among cancer survivors, illness perception may affect patient health-related quality of life and mortality.
Odds of choosing screening up for men with family history, African descent, low socioeconomic status.
Findings for men with intermediate- and high-risk prostate cancer
The USPSTF has updated its 2012 recommendations on prostate-specific antigen (PSA)-based screening for prostate cancer.
Prostate cancer was diagnosed more frequently in men who underwent single prostate-specific antigen screening than in those who did not, but mortality was unaffected.
For men with metastatic prostate cancer, aggressive therapy has no significant advantage over conservative androgen deprivation only treatments.
A positive correlation between increased BMI and risk of prostate cancer recurrence was observed in patients undergoing radical prostatectomy.
Polygenic hazard scores were developed to help predict the age of onset of prostate cancer.
